Introduction
============

Mitral valve disease is the most common valvular heart disorder, while mitral valve regurgitation is the most common pathology with a prevalence of 72% among all mitral valve disorders in industrialized countries ([@ref-4]; [@ref-17]). Mitral valve repair is the gold standard for the treatment of degenerative mitral valve regurgitation ([@ref-2]; [@ref-11]; [@ref-12]).

Minimally invasive mitral valve procedures were introduced into clinical practice in the 1990s and represent a standard approach at specialized centers for mitral valve surgery (MVS). Various recent studies have demonstrated similar or superior outcomes after minimally invasive MVS compared with MVS through conventional median sternotomy (conv-MVS) ([@ref-1]; [@ref-6]; [@ref-7]; [@ref-21]). Despite longer cardiopulmonary bypass (CPB) and cross-clamp times in mini-MVS, this approach led to comparable rates for early mortality, long-term survival and freedom from redo surgery ([@ref-1]; [@ref-9]; [@ref-19]). Furthermore, it was shown that in patients undergoing mini-MVS the occurrence of postoperative complications like mediastinal bleeding, acute renal failure, wound infection, atrial fibrillation, and pacemaker insertion was similar or lower than that in patients undergoing conv-MVS ([@ref-1]; [@ref-5]; [@ref-19]).

The aim of this present study is to investigate the influence of the minimal invasive approach through lateral thoracotomy on outcome and survival. For that, we evaluated preoperative characteristics, operative data, postoperative events, and long-term survival in our patient collective undergoing isolated MVS due to mitral valve regurgitation from 2000 to 2016 in a non-high volume center for valve surgery. For comparing mini-MVS vs conv-MVS a propensity score-matched analysis was generated based on age, sex, co-morbidities, and preoperative clinical data. The clinical outcomes were investigated.

Methods
=======

Study population
----------------

During the period from 2000 to 2016, a total of 669 isolated mitral valve procedures for isolated mitral valve regurgitation were recorded, among them 317 (47.4%) with a minimally invasive approach through right mini-thoracotomy. Degenerative mitral valve disease was the cause of mitral insufficiency in our matched cohort. The patients were divided into two groups: those who underwent mini-MVS and those who underwent conv-MVS via standard sternotomy; 227 pairs were generated.

The matched groups were similar with regard to selected preoperative co-morbidities, and the haemodynamic and demographic categories. All patients undergoing concomitant procedures were excluded. Furthermore, we considered the causes of mitral valve regurgitation; consequently, there was no statistical difference between the cohorts. Postoperative outcomes and major complications such as death, stroke, wound infection, reoperation for bleeding, re-intubation, blood product use, renal failure, atrial fibrillation, hospital and ICU lengths of stay, and survival were analyzed. This study was approved by the local ethics committee of the University of Heidelberg, medical faculty (approval no.: S-516/2016). Furthermore, this study follows the ICMJE Privacy and confidentiality guidelines. The participant consent and follow-up data were obtained by letter correspondence and clinical visits.

Definitions
-----------

Early mortality was defined as death within 30 days after surgery or before discharge from the hospital. Postoperative respiratory failure was defined as re-intubation or tracheotomy. Postoperative stroke was defined as a new and permanent neurological disability or deficit. Postoperative temporary renal failure was defined as new necessity for dialysis during the hospital stay and as permanent renal failure if dialysis was necessary at the time of discharge. Gastrointestinal complications included gastrointestinal bleeding and visceral ischemia. Cardiac decompensation included New York Heart Classification classes III and IV.

Statistical analysis
--------------------

For comparison, the propensity score-matched groups were generated based on variables including demographics, co-morbidities and haemodynamic values. The patients were matched using a 1:1 nearest-neighbour algorithm. The statistical analyses were done using IBM SPSS, version 24 (IBM Corp., Armonk, NY, USA). Categorical data are described as percentages and continuous variables are presented as mean ± standard deviation or the median with the 25th and 75th quartiles. Statistical significance was defined as *p* ≤ 0.05. The mean values were compared using *t*-Student test for normally distributed variables and the Mann--Whitney *U*-test for variables that were not normally distributed. Cumulative survival was described using the Kaplan--Meier method. Categorical variables were compared using chi-square test or Fisher's exact test.
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###### Baseline characteristics, propensity score-matched cohorts.
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  Characteristics                                              Unmatched        Sternotomy    Mini-MVS      *p* (Sternotomy vs mini-MVS)
  ------------------------------------------------------------ ---------------- ------------- ------------- ------------------------------
  *n*                                                          669              227           227           
  Age, years (median; 25th to 75th percentile)                 64; 54--72       63.0          62.0          0.765
  Male                                                         447 (66.8%)      151 (66.5%)   153 (67.4%)   0.842
  Body mass index, kg/m^2^ (median; 25th to 75th percentile)   25.4; 23.1--28   25.4          25.3          0.827
  Diabetes                                                     80 (12%)         22 (9.7%)     32 (14.1%)    0.419
  Hyperlipidemia                                               284 (42.5%)      94 (41.4%)    107 (47.1%)   0.059
  Arterial hypertension                                        490 (73.2%)      164 (72.2%)   162 (71.4%)   0.574
  Pulmonary hypertension                                       299 (44.7%)      96 (42.3%)    100 (44.1%)   0.705
  COPD: Chronic obstructive pulmonary disease                  44 (6.6%)        12 (2.6%)     8 (1.8%)      0.36
  GFR: Glomerular filtration rate \< 60 ml/min                 149 (22.4%)      71 (31.3%)    71 (31.3%)    0.999
  Smoking                                                      203 (30.3%)      69 (30.4%)    71 (31.3%)    0.393
  Sinus rhythm                                                 568 (84.9%)      193 (85.0%)   196 (86.3%)   0.688
  Ejection fraction ≥50%                                       436 (65.9%)      154 (67.8%)   163 (72.1%)   0.513
  Ejection fraction 31--50%                                    162 (24.2)       53 (23.3%)    50 (22.1%)    
  Ejection fraction ≤ 30%                                      42 (6.3%)        10 (4.4%)     6 (2.7%)      
  History of cardiac decompensation                            171 (25.6%)      53 (23.3%)    46 (20.3%)    0.426
  History of cardiopulmonary resuscitation                     11 (1.6%)        6 (2.6%)      1 (0.4%)      0.098
  Stroke preoperatively                                        22 (3.3%)        15 (6.6%)     3 (1.3%)      0.105
  History of cardiac infarction                                79 (11.8%)       26 (11.5%)    18 (7.9%)     0.265
  Syncope                                                      42 (6.3%)        14 (6.2%)     15 (6.6%)     0.596
  History of percutaneous transluminal coronary angioplasty    66 (9.9%)        21 (9.3%)     14 (6.2%)     0.218

Surgical technique
------------------

Our surgical approaches have been previously described in detail ([@ref-1]; [@ref-8]; [@ref-12]). For the conventional MVS, mostly the standard median sternotomy with central bicaval cannulation was used. Briefly, the minimally invasive MVS was performed through a right anterolateral thoracotomy, mostly in the fourth intercostal space and femoral cannulation for cardio-pulmonary bypass was used. Various mitral valve repair techniques were performed. For example, we used ring annuloplasty, leaflet resection (quadrangular or triangular resection), neochordae and commissuroplasty. For the mitral valve replacement, we used the biological prosthesis Hancock II, Perimount Magna prostheses or mechanical St-Jude medical prostheses. In all cases transesophageal echocardiography was performed to evaluate the surgical results.

Results
=======

Baseline characteristic
-----------------------

The median age of the patients in the matched-propensity analysis was 63 and 62 years in the mini-MVS and the conv-MVS group, respectively (*p* = 0.765). The male gender was predominant in both groups. The haemodynamic profiles of the matched patients were comparable in both groups. The demographic characteristics and mitral valve pathology grouped by Carpentier's classification of the propensity-matched cohorts are outlined in detail in [Tables 1](#table-1){ref-type="table"} and [2](#table-2){ref-type="table"}.
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###### Mitral valve pathologies.
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  Carpentier-Classification   Unmatched     Sternotomy    Mini-thoracotomy   *p*
  --------------------------- ------------- ------------- ------------------ -------
  Only 1                      27 (4%)       9 (4%)        10 (4.4%)          0.815
  Only 2                      119 (17.8%)   50 (22%)      39 (17.2%)         0.193
  Only 3                      22 (3.3%)     11(4.8%)      3 (1.3%)           0.03
  Mixed                       492 (73.5%)   156 (68.7%)   172 (75.8%)        0.09
  Prosthetic valve            10 (1.5%)     1 (0.4%)      3 (1.3%)           0.315

Clinical results
----------------

The in-hospital outcomes and complications are summarized in [Table 3](#table-3){ref-type="table"}. In terms of in-hospital mortality, there was a significant difference between the investigated groups (mini-MVS: *n* = 1; 0.4% vs. *n* = 7; 3.1% in conv-MVS; *p* = 0.032). In the mini-MVS group, strokes occurred in 1.8% (*n* = 4) vs 0.9% (*n* = 2) in the conv-MVS group (*p* = 0.264). Furthermore, symptomatic transitory psychotic syndrome was observed in 28 patients (12.3%) in the mini-MVS group, which was similar to the incidence in the conv-MVS group (*n* = 23; 10.1%; *p* = 0.457). Moreover, there were two cases (0.9%) of myocardial infarctions after mini-MVS postoperatively, although these were without statistical significance in comparison with conv-MVS (*p* = 0.562). Exploration due to mediastinal bleeding did not differ significantly between the matched groups (*p* = 0.411). The transfusion requirements were significantly lower in the minimally invasive matched cohorts (*p* \< 0.001). The incidence of postoperative respiratory failure requiring re-intubation (*p* = 0.647) or tracheotomy (*p* = 0.760) were comparable and did not differ significantly. Mini-MVS was at an advantage regarding acute renal failure with a necessity for dialysis (*n* = 6; 2.6% for mini-MVS vs. *n* = 15, 6.6% for conv-MVS; *p* = 0.044). The incidence of sepsis and pneumonia was comparable between the matched groups. The rate of pacemaker implantation did not differ between the analyzed groups (*p* = 0.177). There were one thoracic wound infection without necessity of surgical revision after the anterolateral thoracotomy, whereas one patient had severe wound infection requiring surgical revision in the conventional group (*p* = 1.000). The intensive care duration and the length of stay in hospital were comparable between the groups (*p* = 0.779 and *p* = 0.516), respectively. Postoperatively, both groups presented comparable median pain intensity rated on the visual analogue scale from 0 to 10: mini-MVS had a score 3.4 vs 3.5 for con-MVS (*p* = 0.862). The incidence of phrenic nerve palsy in both groups was comparable (*p* = 0.154).
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###### Postoperative outcomes, stratified by operative approach.
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  Characteristics                                                                   Unmatched     Sternotomy    Mini-MVS      *p* value
  --------------------------------------------------------------------------------- ------------- ------------- ------------- -----------
  Mitral valve repair                                                               397 (59.3%)   105 (46.3%)   184 (81.1%)   \<0.0001
  30-day mortality                                                                  14 (2.1%)     7 (3.1%)      1 (0.4%)      0.032
  Intraoperative mortality                                                          3 (0.4%)      0.0           1 (0.4%)      0.368
  Stroke                                                                            6 (0.9%)      2 (0.9%)      4 (1.8%)      0.264
  Re-exploration                                                                    10 (1.5%)     4 (1.8%)      2 (0.9%)      0.411
  Dialysis                                                                          36 (5.4%)     15 (6.6%)     6 (2.6%)      0.044
  Myocardial infarction                                                             5 (0.7%)      1 (0.4%)      2 (0.9%)      0.562
  Mediastinitis                                                                     0             0.0           0.0           
  Wound infection                                                                   3 (0.4%)      1 (0.4%)      1 (0.4%)      1.000
  Aortic dissection                                                                 0             0.0           0.0           
  Re-intubation                                                                     27 (4%)       9 (4.0%)      11 (4.8%)     0.647
  Tracheotomy                                                                       22 (3.2%)     6 (2.6%)      5 (2.2%)      0.760
  Pacemaker implantation                                                            10 (1.5%)     4 (1.8%)      1 (0.4%)      0.177
  Atrial fibrillation                                                               215 (32.1%)   71 (31.3%)    74 (32.6%)    0.321
  Low cardiac output                                                                50 (7.5%)     18 (7.9%)     8 (3.5%)      0.422
  Transient psychotic syndrome                                                      76 (11.4%)    23 (10.1%)    28 (12.3%)    0.457
  Phrenic nerve palsy                                                               8 (1.2%)      2 (0.9%)      6 (2.6%)      0.154
  Sepsis                                                                            28 (4.2%)     12 (5.3%)     6 (2.6%)      0.149
  Pneumonia                                                                         53 (7.9%)     19 (8.4%)     11 (4.8%)     0.131
  Cardiopulmonary resuscitation                                                     16 (2.4%)     8 (3.5%)      6 (2.6%)      0.587
  Gastrointestinal complications                                                    25 (3.7%)     10 (4.4%)     5 (2.2%)      0.189
  Postoperative pain in subjective 0--10 scale, median; 25th to 75th percentile     3; 1--5       3; 1--5       3; 1--5       0.862
  Intensive care unit length of stay \[days\], median; 25th to 75th percentile      1; 1--3       1; 1--3       1; 1--3       0.779
  Hospital length of stay \[days\], median; 25th to 75th percentile                 13; 9--18     12; 9--18     13; 10--17    0.516
  Length of the mechanical ventilation \[hours\], median; 25th to 75th percentile   17; 13--22    18.89         22.76         0.184

Surgical results
----------------

In the mini-MVS group the median operation time was 282 min and the CPB time was 178 vs. 200 min and 112 min in the conv-MVS cohort. These differences were statistically significant (*p* \< 0.001). The cross-clamp times were significantly longer in the mini-MVS than in the sternotomy cohort (*p* \< 0.001). Patients in the mini-MVS group received mitral valve repair more frequently (81.1% vs. 46.3%; *p* \< 0.001) despite the same distribution of mitral valve apparatus defects ([Table 2](#table-2){ref-type="table"}). No conversion to sternotomy was necessary and there was no case of aortic dissection in our collective. There were 218 patients (96.0%) who underwent mini-MVS and 12 patients (5.3%) who underwent conventional sternotomy using femoral arterial cannulation (*p* \< 0.001); there was aortic cannulation in 18 cases (7.9%) for mini-MVS and in 214 cases (94.7%) for conventional sternotomy (*p* \< 0.001).

Crystalloid cardioplegia was used in all patients in the mini-MVS cohort and in 224 in the conventional cohort. Blood cardioplegia was used only in three cases of the conventional cohort. Five patients (2.2%) in the mini-MVS cohort vs. 13 patients (5.7%) in the conv-MVS group received intra-aortic balloon pump (*p* = 0.018), and only one patient (0.4%) received extracorporeal membrane oxygenation in the conv-MVS group (*p* = 0.317). The surgical data are described in [Table 4](#table-4){ref-type="table"}.
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###### Operative data.
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  Characteristics                                                          Unmatched       Sternotomy     Mini-MVS        *p* value
  ------------------------------------------------------------------------ --------------- -------------- --------------- -----------
  Cardiopulmonary bypass time \[min\], (median; 25th to 75th percentile)   142; 107--187   112; 90--141   178; 148--211   \<0.001
  Cross-clamp time \[min\], (median; 25th to 75th percentile)              88; 64--114     73; 58--92     108; 89--129    \<0.001
  Aortic cannulation                                                       363 (54.3)      214 (94.7%)    18 (7.9%)       \<0.001
  Femoral arterial cannulation                                             321 (48.1%)     12 (5.3%)      218 (96.0%)     \<0.001
  Red blood cell units, total (median; 25th to 75th percentile)            0; 0--2         1; 0--3        0; 0--2         0.001
  Intra-aortic balloon pump                                                36 (5.4%)       13 (5.7%)      5 (2.2%)        0.018
  Extracorporeal life support                                              1 (0.1%)        1 (0.4%)       0.0             0.317

Follow-up results
-----------------

The survival data are illustrated in [Fig. 1](#fig-1){ref-type="fig"}. The median follow-up time was 4.4 years. One-, five-, and 10-year survival rates were 96%, 90%, and 84% after the minimally invasive approach, and 89%, 85%, and 70% after the conventional sternotomy, respectively (log rank *p* = 0.004, Breslow *p* = 0.004). In both the mini-MVS group and in the conv-MVS group there were two valve-related re-operations in each group, (*p* = 0.881). In the mini-MVS cohort the patients were operated on after 30 and 72 months and in the cohort of the conventional approach after 24 and 38 months. At the final follow-up interview, 51 patients (50.5%) were presented at New York Heart Association (NYHA) Classes I and II after minimally invasive surgery which is correspondingly comparable with the conv-MVS group (50.6%, *n* = 44; *p* = 0.727). Furthermore, both groups did not differ with regard to exercise capacity (*p* = 0.153). During the follow-up time, five patients had strokes in the mini-MVS cohort, while no stroke occurred in the conv-MVS cohort, (*p* = 0.036). However, no patient suffered from myocardial infarction in the mini-MVS group, although two patients in the conv-MVS group had myocardial infarction in the follow-up period, (*p* = 0.124). The patients' scar satisfaction regarding the cosmetic results was comparable in the matched groups (*p* = 0.771). The follow-up results are summarized in [Table 5](#table-5){ref-type="table"}.

![Survival curve.](peerj-06-4810-g001){#fig-1}
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###### Follow-up data.
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  Characteristics                                       Unmatched       Sternotomy          Mini-MVS          *p* value
  ----------------------------------------------------- --------------- ------------------- ----------------- -----------
  Median follow-up (years; 25th to 75th percentile)     4.2; 1.8--7.7   4.45; 1.96--10.24   4.44; 2.15--7.4   0.064
  Answered to questionnaire                             189             87                  102               
  During follow-up:                                                                                           
  Myocardial infarction                                 2 (1%)          2 (2.3%)            0.0               0.124
  Stroke                                                5 (2.6%)        0.0                 5 (4.9%)          0.036
  Mitral valve replacement after repair                 4 (2.1%)        2 (2.3%)            2 (2.0%)          0.881
  Pacemaker implantation                                2 (1%)          1 (1.1%)            1 (1.0%)          0.915
  Implantable cardioverter defibrillator implantation   2 (1%)          2 (2.3%)            0.0               0.126
  Heart transplantation                                 1 (0.6%)        0.0                 1 (1.0%)          0.352
  Congestive heart failure                                                                                    
  NYHA class I or less                                  84 (44.4%)      40 (45.9%)          45 (44.1%)        0.727
  NYHA class II                                         72 (38%)        34 (39.1%)          38 (37.6%)        
  NYHA class III                                        30 (15.9%)      11 (12.6%)          19 (18.8%)        
  NYHA class IV                                         3 (1.6%)        2 (2.3%)            1 (1.0%)          
  Exercise capacity                                                                                           
  Good                                                  145 (76.7%)     63 (72.4%)          82 (81.2%)        0.153
  Reduced                                               43 (22.8%)      24 (27.6%)          19 (18.8%)        
  Satisfaction with cosmetic results                    174 (92%)       80 (92.0%)          94 (93.1%)        0.771
  One-year survival                                     93%             89%                 96%               0.004
  Five-year survival                                    85%             85%                 90%               
  Ten-year survival                                     71%             70%                 84%               

Discussion
==========

In our present study, we showed significantly lower early mortality with better long-term survival rates in the mini-MVS cohort. Recent series were also able to demonstrate, that mini-MVS can be performed without significant differences in mortality and long-term survival compared with conventional MVS ([@ref-5]; [@ref-9]; [@ref-15]; [@ref-19]). The elevated stroke rate after mini-MVS as a consequence of peripheral cannulation or retrograde perfusion is considered to be disadvantage of this approach ([@ref-3]). However, some newer publications disprove these findings. Several studies showed no significant differences regarding the incidence of stroke in comparison to both surgical approaches ([@ref-1]; [@ref-6]; [@ref-9]). Modi et al. reported a systemic meta-analysis of six studies, that showed similar stroke rates between mini-MVS and the conventional method ([@ref-14]). In our propensity score-matched analysis, there were also no differences in stroke rates between patients undergoing mini-MVS and conventional sternotomy in the immediate postoperative period. Surprisingly, the mini-MVS cohort developed more strokes in the long-term follow-up than did the conventional cohort. Our follow-up data did not allow us information about whether these strokes are complications of valve-related anticoagulation.

Furthermore, we observed prolonged CPB and cross-clamp times in the mini-MVS cohort. These facts did not influence the early mortality. In contrast, patients undergoing the mini-MVS approach suffered significantly less from renal failure requiring dialysis and showed better early survival. Other authors underline these findings ([@ref-1]; [@ref-5]; [@ref-6]; [@ref-9]; [@ref-19]). Bleeding events, respiratory failure, and wound infection frequencies are comparable with the results of conv-MVS. Similar results were achieved in other contemporary series ([@ref-1]; [@ref-6]; [@ref-9]; [@ref-19]).

The indication for mini-MVS should be well thought out. Not all patients with isolated mitral valve disease are ideal candidates for this approach. Contraindications are very poor left ventricular ejection fraction, obesity, serious lung disease, chest wall depth, or pleural adhesions ([@ref-8]; [@ref-22]). All of these factors must be carefully examined in decision making. In our collective, conversion to conventional sternotomy was not necessary in any case. One of the main aims of minimally invasive surgery is to improve cosmetic results and reduce pain intensity. Cheng et al. showed in a meta-analysis improved patient's scar satisfaction, meanwhile, Svensson and colleagues showed less pain intensity within the first 24 h postoperatively after the minimally invasive approach ([@ref-5]; [@ref-20]). Our matched cohorts showed high satisfaction with the cosmetic results and comparable pain intensity postoperatively in both groups. Previous series examined the influence of minimally invasive surgery on the success of mitral valve repair; it led to similar or superior repair rates. We achieved a remarkably higher mitral valve repair rate among the mini-MVS cohort with 81.1% vs. 46.3% through the conventional approach ([@ref-6]; [@ref-16]; [@ref-19]). During the follow-up time, the incidence of myocardial infarction was low and comparable in both matched groups. However, the mini-MVS cohort showed significantly better long-term survival. Most analyses showed comparable long-term survival after the mini-MVS ([@ref-9]; [@ref-10]; [@ref-15]; [@ref-20]). With regard to mitral valve-related re-intervention, similar results were achieved in our comparison. Recent literature underlines our findings ([@ref-6]; [@ref-7]; [@ref-19]).

Study Limitation
================

The main limitation of our study is its retrospective design; however the follow-up data were obtained prospectively. To our knowledge, this is one of few contemporary propensity score-matched comparisons of MVS that is stratified by operative approaches. Nevertheless, the results of our non-high volume center for MVS are comparable with high-volume centers for MVS. We demonstrated excellent results with a median follow-up time of 4.4 years after mini-MVS. However, the lack of echocardiographic data is an important limiting factor of the follow-up. Furthermore, our data are limited by the lack of consideration of surgeon expertise and operation date in the matching score analysis. However, the expertise of surgeons may have changed over this extended period and the repair technique of mitral valve pathologies have also changed. Furthermore, the better survival after mini-MVS could be translated as a result of higher repair rates in this collective.

Conclusion
==========

Despite the longer operative times, mini-MVS can be considered a safe and equivalent alternative to conventional sternotomy. We were able to show superior short- and long-term survival after mini-MVS. We also showed that mini-MVS leads to higher repair rates with excellent long-term outcomes. One of the most important points in our comparison was to eliminate the preoperative differences with the equal distribution of mitral valve defects. Also in the setting, the minimally invasive approach was superior with regard to the repair rates. Minimally invasive valve surgery offers various advantages over the conventional approach. To compete with rapidly developing percutaneous technologies, these results should encourage us to offer this technique even to elderly patients. In summary, mini-MVS should be preferred if there is a suitable anatomy of the mitral valve and the patient's conditions enable this approach. Furthermore, well-thought-out patient selection is very important for a successful outcome.
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